Topical modulation of PIEZO2 in the cornea emerges as a potential treatment to selectively relief unpleasant sensations and pain associated with mechanical irritation present in many ocular surface disorders
Innerva is developing INE-1001, a topical ophthalmic formulation of a PIEZO2 antagonist, for acute and chronic ocular surface pain